Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Osteoporosis, Post-Menopausal Clinical Trial

Official title:

Efficacy and Safety of Teriparatide 20 Micrograms in the Treatment of Postmenopausal Women With Osteoporosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00532207
• Other study ID #: 8736
• Secondary ID: B3D-MW-GHCR
• Status: Completed
• Phase: Phase 3
• First received: September 18, 2007
• Last updated: September 18, 2007
• Start date: November 2003
• Est. completion date: December 2004

Study information

• Verified date: September 2007
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russia: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2004
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Are postmenopausal women at least 55 years old and at least 2 years postmenopausal at the time of entry into the trial, and who have given informed consent before entering the study and after being informed of the risks, medications, and procedures to be used in the study. In addition, women below the age of 60 years with indeterminate menopause due to premenopausal hysterectomy must have their postmenopausal status confirmed with a serum FSH level > 30 IU/L.

• Posterior-anterior lumbar spine (L1-L4) BMD and/or femoral neck BMD measurement at least < 2.5 standard deviation (SD) from the mean of healthy, pre-menopausal women.

• Results of lumbar BMD (L1-L4) measurement must be available. The initial lumbar spine assessment and the determination of the patient's eligibility for entry into the screening phase will be made by the individual investigator. If the L-1 vertebra cannot be analyzed due to artifact, vertebral fracture, osteophytes, or other abnormalities, that vertebra should be excluded from the analysis.

• Normal or clinically insignificant abnormal laboratory values (as defined by the investigator) including serum calcium, 25 hydroxyvitamin D levels and alkaline phosphatase.

• Willing to be trained on and use a pen type injection delivery system on a daily basis for 12 months.

Exclusion Criteria:

• Active liver disease - liver enzymes (ALT, AST) more than three times the upper normal range, or a bilirubin of > 2.0 mg/dl, or clinical jaundice.

• Abnormal thyroid function not corrected by therapy. Normal thyroid function will be documented by a normal TSH during screening phase

• History of active nephrolithiasis or urolithiasis in the prior 2 years. Patients with any documented history of nephro- or urolithiasis must have had an appropriate imaging procedure within the prior 6 months, such as, an intravenous pyelography (IVP), supine radiograph of the kidney ureter bladder (KUB), or renal ultrasound, which must document the absence of stones

• History of malignant neoplasms within the prior 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. If malignant neoplasm was ever diagnosed, patient must presently be free of disease.

• Current pharmacological treatment for osteoporosis, other than calcium and Vitamin D

• History of Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Post-Menopausal
• Osteoporosis, Postmenopausal

Intervention

Drug:
• teriparatide
subcutaneous 20 micrograms

Locations

Country	Name	City	State
Russian Federation	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To test the hypothesis that therapy for 12 months with once daily subcutaneous PTH 1-34 (teriparatide; TPTD) 20 micrograms will increase Bone Mineral Density (BMD) at the lumbar spine in postmenopausal women with osteoporosis
Secondary	To test the hypothesis that therapy for 3 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis
Secondary	To test the hypothesis that therapy for 12 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis.
Secondary	To evaluate safety of once daily subcutaneous teriparatide 20 micrograms for 12 months.
Secondary	To evaluate effect of teriparatide on changing in femoral neck and total hip BMD
Secondary	To test the hypothesis that treatment with TPTD will favorably affect back pain within the natural course of the disease
Secondary	To test the hypothesis that treatment with TPTD will favorably affect quality of life within the natural course of the disease

External Links

•   Lilly Clinical Trial Registry